BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 14983106)

  • 1. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
    Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.
    Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E
    J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The myelodysplastic syndrome and autoimmunity].
    Laursen SB; Nielsen MØ; Hasselbalch HC
    Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
    Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
    Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
    Hui CH; Horvath N; Lewis I; To LB; Szabo F
    Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
    Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
    Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myelodysplastic syndromes].
    Solary E; Fontenay M
    Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
    Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
    Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
    Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
    Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.